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INTRODUCTION
Rhesus (Rh) D blood group incompatibility between a
pregnant woman and her fetus is a significant problem
due to the possibility of maternal allo-immunization and
consequent severe hemolytic-disease of the fetus and
newborn (HDFN), resulting in hydrops fetalis and fetal
death.1 
For D-negative immunized pregnant women with
heterozygous partner, it is important to know the RhD
type of the fetus to assess the risk of HDFN. This
involves intrauterine testing by which the fetal RhD
status can be predicted with high degree of accuracy by
polymerase chain reaction (PCR) amplification of fetal
DNA extracted from amniocytes or chorionic villi.2 Pre-
natal determination of RhD status in these cases is
clinically useful because no further testing or therapeutic
procedures will be necessary if the fetus is D- negative.3
If the fetus is D-positive, further studies will be required
to demonstrate the level of fetal hemolysis by invasive
testing.4 In Pakistan, invasive procedures carry as high
as 5% risk of inducing spontaneous miscarriage5 and is
not widely available, with few centres carrying out
invasive testing across the country. Furthermore, this
procedure causes a significant risk of enhancing
maternal antibody levels in allo-immunized women.6 On
the other hand, non-sensitized D-negative mothers are
offered anti-D prophylaxis routinely in the third trimester.7
This exposes them to unnecessary administration of
anti-D as 40% of them carry a D-negative fetus.8
Based on the methods devised by the SAFE (special
non-invasive advances in fetal and neonatal evaluation)
network of excellence,9 fetal RhD status can be
identified using fetal DNA extracted from maternal plasma
samples from D-negative women with serologically
positive spouse. The objective of this study was to
determine the accuracy of the non-invasive pre-natal
determination of real-time polymerase chain reaction
based fetal RhD genotyping from maternal plasma.
METHODOLOGY
Peripheral blood samples (5-10 ml) were collected from
21 D-negative pregnant women visiting the Aga Khan
Hospital for Women and Children, Kharadar, Karachi
(Aga Khan Health Services, Pakistan) between 20-39
weeks of gestation, during routine pre-natal visit from
July to December 2008. Ten ml blood sample was also
collected from D-positive woman to establish the real-
time PCR system and to use as positive control.
Informed consent was obtained from the women before
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drawing the blood. Approval for the study was provided
by the Aga Khan University Hospital Ethics Review
Committee. All the samples were brought to the Aga
Khan University, Juma Health Sciences Research Lab
within 24 hours of collection for further processing. Fetal
RhD status was unknown at the time of collection; it was
later confirmed with serological D typing on cord blood
taken routinely at birth. 
The EDTA blood was transferred into 15 ml polypropylene
centrifuge tubes (Alpha Laboratories, Hampshire, UK)
and centrifuged at 2760 rpm for 15 minutes. The exact
volume of the blood and plasma obtained was recorded.
Care was taken to ensure that the buffy coat was not
disturbed. Maternal leukocytes obtained from the buffy
coat were utilized as D-negative control. Plasma
aliquots were prepared in 1.5 ml Appendorf tubes and
stored at -80oC until further processing. On the day of
analysis, the plasma was thawed and again centrifuged
at 14000 rpm for 15 minutes. Aerosol resistant tips
(Molecular BioProducts Inc, San Diego, CA) were used
for plasma separation and extraction of DNA. 
DNA was extracted from the Rh-negative maternal
leukocytes by use of the QIA amp Blood Mini Kit
(Qiagen, Hilden, Germany) according to the protocol
recommended by the manufacturer. An elution volume
of 100 µl was used for the final washing. The purity and
the yield obtained were measured using the mass
spectrophotometer, Beckman_DU 650 (Beckman Coulter,
Fullerton, CA) where the A260/A280 ratio between 1.8
and 2.1 was considered acceptable.
DNA was extracted from the plasma by use of the QIA
amp Blood Mini Kit (Qiagen, Hilden, Germany). The
volume of the plasma used was between 1-2 ml. The
reagent volumes were scaled upto accommodate the
increased plasma volume in each extraction. Extractions
were performed in 400 µl aliquots and used 40 µl of
proteinase K (Qiagen, Hilden, Germany) for digestion.
The samples were loaded on the spin-column by
repeated centrifugation and the DNA was eluted in 60 µl
of elution buffer. Before elution, the columns and elution
buffer were pre-warmed to 55oC for 5 minutes on a
heating block. DNA extraction was performed in a class-
II safety cabinet (The Baker Company, Exton, PA).
Real-time PCR procedure was established for the RhD
gene system according to the Safe Network Protocol
with modifications. Real-time quantitative PCR analysis
was performed in the Chromo4 Real-time PCR Detector
(BioRad, Hercules, CA), which is a combined thermal
cycler/fluorescence detector. In addition to the two
amplification primers, RhD exon 5 forward 5’CGC CCT
CTT CTT GTG GAT G3’ and reverse 5’GAA CAC GGC
ATT CTT CCT TTC3’, a dual-labeled fluorogenic
hybridization probe 5’(FAM) TCT GGC CAA GTT TCA
ACT CTG CTC TGC T (BHQ) 3’)1 was also included.
One fluorescent dye (6 carboxyfluorescein FAM) served
as a reporter while its emission was quenched by a
second reporter dye (black hole quencher BHQ). The
primers and probe were targeted towards the exon 5
region of the RhD gene1. β-globin forward 5’GTG CAC
CTG ACT CCT GAG GAG A 3’; β-globin reverse 5’CCT
TGA TAC CAA CCT GCC CAG 3’; and β-globin probe
5’(FAM) AAG GTG AAC GTG GAT GAA GTT GGT GG
(BHQ) 3’ was used as a house-keeping gene to detect
the presence of total DNA. The high-performance liquid
chromatography-purified primers and probes were
obtained from BioSearch Technologies Inc, (Novato,
CA). The primers and probes arrived in lipholysed form
which were then dissolved in 1X Tris buffer pH 8.0 and
used at a final concentration of 100 mM.    
All the samples were run in duplicate in a reaction
volume of 25 µl with 5 µl DNA. Reaction conditions were
as follows: 1X Go Flexi colorless buffer (Promega,
Madison, WI), 5.5 mM MgCl2 (Promega, Madison, WI),
0.2 mM of each DNTPs (deoxyribo-nucleotide
phosphates) (Promega, Madison, WI), 450 nM forward
and 450 nM reverse primers, 125 nM of TaqMan probe
(BioSearch Technologies Inc., Novato, CA) and 1 U of
Taq Polymerase (Promega, Madison, WI). PCR was
performed for 50 cycles with 5 minutes initial heating at
95oC, 15 seconds denaturation at 95oC and 1 minute
annealing and extension at 55oC. To ensure quality of
the RhD PCR assay, control reactions containing
D-positive and D-negative DNA were included with
every experiment. Water-blanks were also included with
all the reactions as negative-control to detect possible
contamination. Strict anti-contamination precautions
were implemented throughout the experiments.  
Positive predictive value was obtained by calculating
proportion of D-positive neonates that were identified to
have D-positive status antenatally.  Negative predictive
value was obtained by taking proportion of D-negative
neonates that were determined antenatally to have
D-negative status. The 95% confidence intervals were
calculated using Epi Info version 6.10
The RhD PCR system was established according to the
Safe Network protocol with minor modifications. To
detect the sensitivity of the assay, the minimum
detectable DNA was identified by serially diluting DNA
enriched from a D-positive blood sample. A total of four
1:10-dilutions in distilled autoclaved water were
prepared and ran with each assay (Figure 1A). Standard
curve formation revealed that as the total DNA
decreased, the minimum cycles required to produce
detectable amounts of the fluorescent reporter molecule
increased (Figure 1B).
RESULTS
The total minimum detectable DNA was 18 Genomic
Equivalence (GE). Of the 21 D-negative women, 13
were identified to have D-positive neonates and 8 to
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have D-negative neonates at birth by serological testing
on cord blood samples. Of the 13 D-positive neonates,
12 were antenatally correctly predicted to be positive for
exon 5 of RhD gene sequence in maternal plasma with
one false-negative result. Five out of 8 D-negative
neonates were antenatally predicted to have absence of
RhD gene sequence. There were three false-positive
results (Table I). The sensitivity and specificity of the
assay was 92.3% (95% CI: 62.1, 99.6) and 62.5% (95%
CI: 25.9, 89.8), respectively. The positive and negative
predictive value of the assay was 80% (95% CI: 51.4,
94.7) and 83.3%  (95% CI: 36.5, 99.1), respectively.  The
level of accuracy in the 21 samples analyzed was found
to be 80%. To validate the presence of DNA, β-globin
was employed as a positive control. β-globin gene was
found in all the plasma samples. DNA extracted from
D-positive maternal sample and D-negative maternal
sample was included in all the assays. Figure 2
illustrates the results of the real-time RhD PCR system
from DNA enriched from three maternal plasma samples,
of which two were diagnosed to carry D-positive fetuses
and one was diagnosed as carrying D-negative fetus.
DISCUSSION
Our prospective preliminary study demonstrates 80%
accuracy of non-invasive fetal RhD genotyping using
DNA extracted from plasma of serologically verified
D-negative women. SAFE Network is a European Union
funded network that aims to optimize current protocols
used for the non-invasive detection of the fetal RhD
status so as to determine the efficacy of this technology
in large multicentre clinical studies.9
Since the first report of successful isolation of cell-free
fetal DNA from maternal circulation by Lo and his
group,11 several groups have utilized this novel
technology for non-invasive identification of fetal RhD
status from maternal circulation.1,3,12,13 Currently, three
centres across Europe namely in Bristol UK,
Netherlands, and France are offering this state-of-the-
art technology as a clinical service.2,14,15 In Pakistan,
this group is the first to carry out this preliminary
investigation. 
False-positive results could be due to genetic variations
in our population since this assay only targeted the exon
5 region. The method employed was based on the Safe
Network protocol, designed according to the genotypes
found in the Caucasian population. Due to the genetic
complexity of the RhD gene system, deletions in other
regions which may give rise to a serological negative
test could have resulted in RhD positive genotype.13 This
is commonly observed in people of African descent
where the RhD pseudogene occurs with considerable
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Figure 1A:  Sensitivity of the RhD PCR system. The minimum DNA detected
was 18GE.
Figure 1B:  Real time fluorogenic RhD PCR analysis of four-1:10 serially
diluted samples. Standard curve depicts the relationship between DNA
concentration and C1 value. The C1 value increases as the DNA
concentration decreases.
Table I: Results of RhD genotyping of fetuses of RhD negative women.
Fetal RhD genotyping at birth (cord blood)
Fetal RhD genotyping RhD-positive RhD-negative Total
from maternal plasma
RhD-positive 12 3 15
RhD-negative 1 5 6
Total 13 8 21
Figure 2:  Presence of fetal RhD DNA in maternal samples using real-time
PCR fluorogenic detection for the exon 5 region. The controls include D-
positive and D-negative DNA from maternal white blood cells. The figure
shows two D-positive fetuses and one D-negative fetus.
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high frequency.16 The Safe Network is currently devising
a multiplex assay which will target all the commonly
deleted regions.17 However, the study is being carried
out on the Caucasian populations which may comprise
a different polymorphic pattern compared to our
population. Even though strict anti-contamination
techniques were employed, contamination could be
possible during sample handling and transport resulting
in false-positive outcomes. The false negative result
noted in this study could be due to either absence of
fetal DNA in the maternal plasma sample analyzed, low
circulating fetal DNA concentrations, fetal DNA loss
during sample processing or failure to amplify the DNA.
Standard procedures use the Y-chromosome sequences
as positive controls to prove the presence of fetal DNA
in maternal circulation.18 This cannot serve adequately
as positive controls as they are only applicable to
pregnancies carrying a male fetus. 
Recently, it has been demonstrated that epigenetic
modifications in fetal DNA differ from the maternal DNA
in the placenta19 and could be used as a positive control
to confirm the presence of fetal DNA in the maternal
plasma sample, hence, eliminating the possibility of
false-negative results.20
Future work in Pakistan would require firstly, a large
scale population study in order to determine the RhD
gene sequence polymorphisms in various ethnic groups.
This information would help us identify whether there is
a complete deletion of the RhD gene or are there any
variants existing according to ethnicity.  This will help in
correctly diagnosing the fetal RhD genotype by
developing specific primer and probe combinations.
Secondly, validation of the RhD PCR system would be
required on a larger sample size in our population.
CONCLUSION
Maternal plasma based assay for non-invasive pre-natal
diagnosis of fetal RhD genotype provided markedly
accurate results obviating the need for invasive
procedure and enabling targeting of pregnancies that
need close monitoring.  Further, fetal RhD typing in non-
sensitized pregnant women in early pregnancy can
allow reduced anti-D administration and less exposure
to human blood products.
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